---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-045343"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:38:30.334174+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart

## Summary
- KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.
- GAAP EPS $0.17 (diluted), net income $8.7M vs $0.9M in Q3 2023; cash $901.3M at Sept 30, 2024.
- CFO Brian Di Donato to leave end of 2024; search for replacement in progress.
- Brenetafusp (PRAME-A02) Phase 1 data at ESMO; NSCLC signal-detection shift delays initial data release.
- Plans to repay $50M loan by end of 2024; pay ~$40M in sales-related rebate accruals in Q4.

## SEC filing metadata
- accession: 0001140361-24-045343
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/0001140361-24-045343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/ef20038108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-045343
- JSON: https://secwatch.observer/filing/0001140361-24-045343.json
- Plain text: https://secwatch.observer/filing/0001140361-24-045343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.